Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) Research & Development (2016 - 2024)

NovaBay Pharmaceuticals (NBY) has disclosed Research & Development for 15 consecutive years, with $10000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Research & Development rose 600.0% to $10000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $42000.0, a 8.7% decrease, with the full-year FY2024 number at $42000.0, up 23.53% from a year prior.
  • Research & Development was $10000.0 for Q4 2024 at NovaBay Pharmaceuticals, up from $4000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $125000.0 in Q3 2020 to a low of -$2000.0 in Q4 2023.
  • A 5-year average of $29600.0 and a median of $15000.0 in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 725.0% in 2022, then crashed 103.03% in 2023.
  • NovaBay Pharmaceuticals' Research & Development stood at $36000.0 in 2020, then plummeted by 77.78% to $8000.0 in 2021, then soared by 725.0% to $66000.0 in 2022, then plummeted by 103.03% to -$2000.0 in 2023, then surged by 600.0% to $10000.0 in 2024.
  • Per Business Quant, the three most recent readings for NBY's Research & Development are $10000.0 (Q4 2024), $4000.0 (Q3 2024), and $9000.0 (Q2 2024).